Cite
HARVARD Citation
Frey, N. et al. (2021). Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence. Clinical pharmacology & therapeutics. 110 (5), pp. 1162-1163. [Online].